294 related articles for article (PubMed ID: 37004060)
1. Integrative analysis of a novel super-enhancer-associated lncRNA prognostic signature and identifying LINC00945 in aggravating glioma progression.
Yang Z; Zheng Y; Wu H; Xie H; Zhao J; Chen Z; Li L; Yue X; Zhao B; Bian E
Hum Genomics; 2023 Mar; 17(1):33. PubMed ID: 37004060
[TBL] [Abstract][Full Text] [Related]
2. Identification of an epithelial-mesenchymal transition related long non-coding RNA (LncRNA) signature in Glioma.
Tao C; Luo H; Chen L; Li J; Zhu X; Huang K
Bioengineered; 2021 Dec; 12(1):4016-4031. PubMed ID: 34288803
[TBL] [Abstract][Full Text] [Related]
3. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
[TBL] [Abstract][Full Text] [Related]
4. A TGF-β signaling-related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy response.
Duan WW; Yang LT; Liu J; Dai ZY; Wang ZY; Zhang H; Zhang X; Liang XS; Luo P; Zhang J; Liu ZQ; Zhang N; Mo HY; Qu CR; Xia ZW; Cheng Q
CNS Neurosci Ther; 2024 Apr; 30(4):e14489. PubMed ID: 37850692
[TBL] [Abstract][Full Text] [Related]
5. A Novel lncRNA Panel Related to Ferroptosis, Tumor Progression, and Microenvironment is a Robust Prognostic Indicator for Glioma Patients.
He Y; Ye Y; Tian W; Qiu H
Front Cell Dev Biol; 2021; 9():788451. PubMed ID: 34950662
[No Abstract] [Full Text] [Related]
6. Comprehensive analysis of oxidative stress-related lncRNA signatures in glioma reveals the discrepancy of prognostic and immune infiltration.
Shi Z; Wu Y; Zhuo Q; Zuo Y; Lin J; Shi H; Zhou H; Xu Z
Sci Rep; 2023 May; 13(1):7731. PubMed ID: 37173373
[TBL] [Abstract][Full Text] [Related]
7. Identification of Prognostic Signature of Necroptosis-Related lncRNAs and Molecular Subtypes in Glioma.
Zhang G; Chen R; Zhu L; Ma H; Tang H; Shang C; Wang J; Zhang D; Li Q; Liu J
Comput Math Methods Med; 2022; 2022():3440586. PubMed ID: 36110575
[TBL] [Abstract][Full Text] [Related]
8. An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients.
Xia P; Li Q; Wu G; Huang Y
Cell Mol Neurobiol; 2021 Mar; 41(2):365-375. PubMed ID: 32410107
[TBL] [Abstract][Full Text] [Related]
9. Super-enhancer-associated TMEM44-AS1 aggravated glioma progression by forming a positive feedback loop with Myc.
Bian E; Chen X; Cheng L; Cheng M; Chen Z; Yue X; Zhang Z; Chen J; Sun L; Huang K; Huang C; Fang Z; Zhao B; Li J
J Exp Clin Cancer Res; 2021 Oct; 40(1):337. PubMed ID: 34696771
[TBL] [Abstract][Full Text] [Related]
10. A novel prognostic related lncRNA signature associated with amino acid metabolism in glioma.
Lei Q; Yuan B; Liu K; Peng L; Xia Z
Front Immunol; 2023; 14():1014378. PubMed ID: 37114036
[TBL] [Abstract][Full Text] [Related]
11. An immune-related lncRNA signature for patients with anaplastic gliomas.
Wang W; Zhao Z; Yang F; Wang H; Wu F; Liang T; Yan X; Li J; Lan Q; Wang J; Zhao J
J Neurooncol; 2018 Jan; 136(2):263-271. PubMed ID: 29170907
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic insights into super-enhancer-driven genes as prognostic signatures in patients with glioblastoma.
Chen Y; Pan Y; Gao H; Yi Y; Qin S; Ma F; Zhou X; Guan M
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12315-12332. PubMed ID: 37432454
[TBL] [Abstract][Full Text] [Related]
13. Characterization of sialylation-related long noncoding RNAs to develop a novel signature for predicting prognosis, immune landscape, and chemotherapy response in colorectal cancer.
Zhou M; Lv S; Hou Y; Zhang R; Wang W; Yan Z; Li T; Gan W; Zeng Z; Zhang F; Yang M
Front Immunol; 2022; 13():994874. PubMed ID: 36330513
[TBL] [Abstract][Full Text] [Related]
14. Profiling pro-neural to mesenchymal transition identifies a lncRNA signature in glioma.
Liang Q; Guan G; Li X; Wei C; Wu J; Cheng P; Wu A; Cheng W
J Transl Med; 2020 Oct; 18(1):378. PubMed ID: 33028341
[TBL] [Abstract][Full Text] [Related]
15. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive analyses indicated the association between m6A related long non-coding RNAs and various pathways in glioma.
Chen Z; Zhang W; Yan Z; Zhang M
Cancer Med; 2023 Jan; 12(1):760-788. PubMed ID: 35668574
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
Zhang C; Liu H; Xu P; Tan Y; Xu Y; Wang L; Liu B; Chen Q; Tian D
BMC Cancer; 2021 Mar; 21(1):251. PubMed ID: 33750353
[TBL] [Abstract][Full Text] [Related]
18. A novel disulfide death-related genes prognostic signature identifies the role of IPO4 in glioma progression.
Wu H; Yang Z; Chang C; Wang Z; Zhang D; Guo Q; Zhao B
Cancer Cell Int; 2024 May; 24(1):168. PubMed ID: 38734657
[TBL] [Abstract][Full Text] [Related]
19. A Novel Inflammatory lncRNAs Prognostic Signature for Predicting the Prognosis of Low-Grade Glioma Patients.
Xiang Z; Chen X; Lv Q; Peng X
Front Genet; 2021; 12():697819. PubMed ID: 34408772
[TBL] [Abstract][Full Text] [Related]
20. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer.
Wei C; Liang Q; Li X; Li H; Liu Y; Huang X; Chen X; Guo Y; Li J
J Cell Biochem; 2019 Sep; 120(9):14916-14927. PubMed ID: 31016791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
